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Abstract
Methyl jasmonate (MJ) acts both in vitro and in vivo against various cancer cell lines. Activation of the phospha-
tidylinositol 3-kinase (PI3K)/Akt pathway results in decreased susceptibility to cytotoxic agents in many types of
cancer cells. We found a strong inverse correlation between the basal level of phospho-Akt (pAkt) and the sensi-
tivity to MJ among sarcoma cell lines. Nevertheless, levels of pAkt increased in two sarcoma cell lines, MCA-105
and SaOS-2, after MJ treatment. Treatment of both cell lines with PI3K/Akt pathway inhibitors in combination with
MJ resulted in a synergistic cytotoxic effect. Moreover, cells transfected with a constitutively active Akt were less
susceptible to MJ-induced cytotoxicity in comparison with cells transfected with an inactive form of Akt. Taken
together, these data suggest that the increase in pAkt after treatment with MJ played a protective role. Because it
has been shown that the antiapoptotic effects of Akt are dependent on glycolysis, we examined the role of glucose
metabolism in activation of Akt and the subsequent resistance of the cell lines to MJ. 2-Deoxy-D-glucose, a gly-
colysis inhibitor, decreased the levels of pAkt and was able to attenuate the MJ-induced elevation in pAkt. Accord-
ingly, the presence of glucose attenuated MJ-induced cytotoxicity. Moreover, treatment with 2-deoxy-D-glucose in
combination with MJ resulted in a synergistic cytotoxic effect. In conclusion, the PI3K/Akt pathway plays a critical
role in the resistance of MCA-105 and SaOS-2 sarcoma cell lines toward MJ-induced cytotoxicity.
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Introduction
Jasmonates are a group of plant stress hormones that are produced in
plants upon exposure to various types of stress. Several groups have
reported in recent years that members of the plant stress hormones
family of jasmonates, and some of their synthetic derivatives, exhibit
anticancer activity in vitro and in vivo. The initial report [1] indicated
that jasmonates can induce both death and suppression of cellular
proliferation in various human and mouse cancer cell lines, including
breast, prostate, melanoma, lymphoblastic leukemia, and lymphoma
cells. Jasmonates were also found to suppress the proliferation or kill
various other cancer cells including lung carcinoma and myeloid leu-
kemia cells [2,3]. Furthermore, jasmonates increased the life span of
EL-4 lymphoma-bearing mice [1] and exhibited selective cytotoxicity
toward cancer cells while sparing normal blood lymphocytes, even
when the latter were part of a mixed population of leukemic and nor-
mal cells drawn from the blood of chronic lymphocytic leukemia pa-
tients [1,4].
The phosphatidylinositol 3-kinase (PI3K)/Akt (also known as pro-
tein kinase B) pathway regulates fundamental cellular functions, such
as transcription, translation, proliferation, growth, and survival, and
is often overactivated in a wide range of tumor types [5–7]. Akt is a
serine/threonine kinase that is recruited to the plasma membrane and
is activated by phosphorylation in response to growth factor or stress
signaling. Once activated, Akt modulates the function of numerous
downstream substrates involved in the regulation of survival, growth,
and cell cycle progression. This modulation includes inhibition of
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proapoptotic factors such as BAD [8] and caspase-9 [9] and activa-
tion of antiapoptotic factors such as IKK [10] and CREB [11].
In addition to its role in the biology of human tumors, this path-
way also plays a major part in the resistance of tumor cells to con-
ventional anticancer therapies [12]. It has been shown in several
studies that elevated Akt activity attenuates the sensitivity of cancer
cell lines toward different chemotherapeutic agents such as vincris-
tine, staurosporine, and TRAIL [13–15]. In addition, phospho-Akt
(pAkt) expression level has been found to be a significant prognosti-
cator in patients with different types of cancers such as breast cancer
[16], gastric carcinoma [17], and soft-tissue sarcomas (STSs) [18].
Blocking the PI3K/Akt pathway could therefore simultaneously in-
hibit the proliferation and growth of tumor cells and sensitize them
toward different cytotoxic agents.
Sarcoma is a general class of cancers that originate from connective
tissues such as fat, muscle, nerve, bones, and cartilage. Although a rela-
tively less common type of cancer, the incidence of sarcoma is not negli-
gible, with 15,000 new STS and osteosarcoma (OS) cases diagnosed in
the United States every year [19]. First-line chemotherapy yields disap-
pointing results in advanced STS. Doxorubicin and ifosfamide are the
most active drugs in the treatment of patients with STS; however, failure
of these drugs leaves patients with very few therapeutic options [20].
Like other cancers, sarcomas seem to have abnormally activated
growth factor signaling pathways. The most common growth factor
pathways that seem to be activated in a variety of sarcomas include
the insulin-like growth factor 1 receptor pathway in rhabdomyosar-
comas and leiomyosarcomas, the PDGFR pathway in desmoplastic
round cell tumors and OSs, the c-KIT receptor pathway in Ewing’s
sarcomas, and the c-MET–receptor pathway in synovial sarcomas
and rhabdomyosarcomas.
A convergence point of activation of these growth factor receptors
is downstream activation of PI3K-AKT [21]. Several studies have in-
dicated that Akt functions as a predominant molecule in different
sarcoma tumors [22,23]. In addition, Akt expression has been shown
to possess a significant prognostic value in STSs [18]. In that study,
elevated pAkt levels were in correlation with poor disease-free and
overall survival. Moreover, a recent study showed that Akt inhibition
results in significant antitumor activity against human STS in vitro
and in vivo [24].
Hexokinase (HK) is the initial enzyme in the glycolytic pathway.
Hexokinase types I and II can associate with the mitochondrial mem-
brane protein voltage-dependent anion channel (VDAC). Dissocia-
tion of HK from VDAC leads to mitochondrial perturbation and
promotes cell death [25,26]. In cancer cells, HK binding to mitochon-
dria and VDAC expression are elevated [27]. The elevated levels of
mitochondria-bound HK in cancer cells, as well as its glucose phos-
phorylation activity, are suggested to play a pivotal role in cancer cell
growth rate and survival by both improving energy supplies and pro-
tecting against mitochondria-mediated cell death [28,29]. Indeed, HK
is considered as an attractive target for anticancer therapy [30,31]. Fur-
thermore, it has been shown that mitochondria-bound HK is found
in sarcoma cells [32].
The specific connection between Akt signaling and mitochondrial
HK in the regulation of cell death has been studied in rat fibroblasts.
Prevention of apoptosis by Akt depends on mitochondrial HK
[26,33,34]. In a recent paper published by our group, methyl jasmo-
nate (MJ) was shown to bind to and detach HK from the mito-
chondria of various cancer cells [35]. In addition, MJ induces the
detachment of HK from mitochondria isolated from MCA-105 cells
(results not shown). Thus, the interaction between MJ and HK, taken
together with the data regarding the Akt-HK axis, led us to investigate
the effect of MJ on the PI3K/Akt pathway.
The aim of our study was to examine the involvement of the PI3K/
Akt pathway in the cytotoxic effect of MJ toward various cancer cell
lines, particularly sarcoma cell lines. We found that the reduced sus-
ceptibility to MJ was in correlation to pAkt levels in the sarcoma cell
lines. Methyl jasmonate treatment led to an increase in pAkt levels
in several cell lines, which could be attenuated using PI3K/Akt in-
hibitors, compromising the cells’ ability to resist the cytotoxic effect
of MJ. Expression of a constitutively active Akt protected the cells
from MJ-induced cytotoxicity. Taken together, these data suggest that
the increase in pAkt after treatment with MJ played a protective role.
In addition, we examined the relationship between Akt and glucose
metabolism in the susceptibility of the cell lines to MJ. The signaling
between Akt and glucose metabolism is bidirectional: Akt regulates
glucose metabolism by various mechanisms such as increased glycolysis
and glucose uptake, whereas glucose is required for the antiapoptotic
functions of both native and constitutive forms of Akt [33,36,37].
We found that the presence of glucose attenuatedMJ-induced cyto-
toxicity. Moreover, we found that treatment with 2-deoxy-D-glucose
(2-DG), a glycolysis inhibitor, in combination with MJ resulted in a
synergistic cytotoxic effect. 2-Deoxy-D-glucose decreased the levels of
pAkt and was able to attenuate the MJ-induced elevation in pAkt.
Thus, blocking glycolysis is an additional approach to inhibit the ac-
tivity of Akt and to sensitize the cells to the cytotoxic effect of MJ.
Materials and Methods
Reagents
Methyl jasmonate [methyl 3-oxo-2-(2-pentenyl) cyclopentaneacetic
acid] and 2-DG were purchased from Sigma-Aldrich Chemie GmbH
Steinheim, Germany. Akt inhibitor 1 (1L6-hydroxymethyl-chiro-
inositol-2-(R)-2-O-methyl-3-O-octadecyl-sn-glycerocarbonate) and the
PI3K inhibitor, wortmannin, were purchased from Calbiochem, San
Diego, CA. Methyl jasmonate was dissolved in ethanol to give a stock
solution of 500 mM. Akt inhibitor 1 and wortmannin were dissolved
in DMSO to give stock solutions of 25 and 50 mM, respectively. 2-
Deoxy-D-glucose was dissolved in culture medium. Further dilutions
were performed in culture medium. The final concentrations of ethanol
and DMSO did not exceed 0.6% and 0.1%, respectively.
Cell Lines and Growth Conditions
CT-26 murine colon carcinoma, A-549 human lung carcinoma
and B-16 murine melanoma were purchased from the American
Type Culture Collection (Rockville, MD).
MCA-105 murine fibrosarcoma cells were kindly provided by Prof.
Ronit Sagi Eisenberg (Tel Aviv University, Israel). SK human leiomyo-
sarcoma cells were kindly provided by Prof. Lea Eisenbach (Weizmann
Institute of Science, Rehovot, Israel). SaOS-2 human OS cells were
kindly provided by Prof. Levana Sherman (Tel Aviv University, Israel).
HCT-116 human colon carcinoma cells were kindly provided by Dr.
Bert Vogelstein (Johns Hopkins University, Baltimore, MD). RD
human rhabdomyosarcoma cells were kindly provided by Prof. Haim
Werner (Tel Aviv University, Israel). All cell lines were maintained
in Dulbecco’s modified Eagle’s medium (Biological Industries, Beit-
Haemek, Israel) supplemented with 10% FCS, 2 mM L-glutamine,
100 U/ml penicillin, 100 μg/ml streptomycin, 1 mM sodium pyruvate,
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and 1:100 dilution of nonessential amino acids (all purchased from Bio-
logical Industries). For experiments of cytotoxicity in the absence of
glucose, Dulbecco’s modified Eagle’s medium without glucose was used
(GIBCO-Invitrogen, Paisley, Scotland, UK).
Cytotoxicity Assay
Cells were plated into 96-well microtiter plates (Corning, Inc.,
Corning, NY) at a density of 3 × 103 cells per well and were allowed
to adhere before treatment. The cells were exposed to MJ, Akt inhibi-
tor 1, wortmannin, 2-DG, or their combinations at different concen-
trations for 16 hours. Akt inhibitor 1, wortmannin, and 2-DG were
added 1 hour before MJ addition.
Cell proliferation was determined using the 2,3-bis(2-methoxy-4-
nitro-5-sulphophenyl)-2H -tetrazolium-5-carboxanilide (XTT) kit.
The assay is based on the ability of metabolic active cells to reduce
the tetrazolium salt XTT to orange compounds of formazan. The
dye formed is water-soluble, and the dye intensity is read at a given
wavelength (490 nm) with a VERSAmax microplate ELISA reader
(Molecular Devices, Sunnyvale, CA). Optical density is directly pro-
portional to the number of living cells in culture. Cytotoxicity (%) was
calculated as follows: [(absorbance of control cells − absorbance of
drug-treated cells)/absorbance of control cells] × 100.
Detection of Protein Levels—Western Blot
Cells were seeded in six-well plates at 0.7 × 106 cells per well and
allowed to adhere. After treatment with the relevant substances, cells
were trypsinized and centrifuged at 1500 rpm for 5 minutes. Cells
were washed with PBS and incubated with 60 μl of lysis buffer
(50 mM Tris-HCl, 5 mM EDTA, 150 mM NaCl, 0.5% deoxycholic
acid, 1% NP-40, 1 mM sodium orthovanadate, and 0.2% protease
inhibitor cocktail; Sigma-Aldrich Co., St. Louis, MO) for 1 hour on
ice. The protein concentration of the sample was determined by
BioRad Dc Protein Assay (Bio-Rad Laboratories Inc., Hercules,
CA). Protein extracts were mixed with sample buffer (5:1), consisting
of 60 mM Tris, pH 6.8, 3% sodium dodecyl sulfate (SDS), 10% glyc-
erol, 5% 2-mercaptoethanol, and 0.05% bromophenol blue, and were
boiled for 5 minutes. Protein samples (30 μg of whole-cell lysate) were
subjected to SDS–polyacrylamide gel (12%) electrophoresis (SDS-
PAGE) followed by immunoblot analysis at 4°C overnight using the
following primary antibodies: anti-pAkt (Ser473), anti–phospho-
GSK-3α/β (Ser21/9), anti–total-Akt (all at 1:1000; Cell Signaling,
Beverly, MA), and antiactin (at 1:500; Santa Cruz Biotechnology,
Santa Cruz, CA). Primary antibodies were detected using horseradish
peroxidase–conjugated secondary antibodies (1:10,000) for 1 hour. The
targeted protein was revealed by enhanced chemiluminescence (ECL).
The membrane was incubated with an ECL solution (Biological Indus-
tries) and exposed to ECL film (Eastman Kodak, Rochester, NY).
Transient Transfection
The expression constructs pCMV5-myr wt PKB and myr KD (in-
active) PKB K179A containing a myristoylation sequence were a
kind gift from Prof. Alex Levitzki (Hebrew University, Jerusalem,
Israel). Permuted enhanced green fluorescent protein was purchased
fromClontech,MountainView, CA. For transfections, cells were seeded
into 24-well plates at a density of 0.4 × 105 cells per well. A mix of
preincubated Metafectene transfection reagent (Metafectene Biontex
Laboratories, Germany) and DNA (ratio of 5:2) was added to the wells.
After overnight incubation, medium in wells was replaced with a fresh
medium, and cells were incubated for 48 additional hours, during which
cells were subjected to different treatments.
To evaluate transfection efficiency, cotransfection of the rele-
vant plasmid and the EGFP plasmid was performed. The fraction
of transfected cells was evaluated using a fluorescent microscope
(IX51; Olympus, Tokyo, Japan).
Flow Cytometric Analysis of Cell Death
Cells were seeded in 24-well plates at a density of 0.4 × 105 cells
per well and were allowed to adhere. After transfection and treatment
with the relevant substances, cells were harvested and stained with
propidium iodide (PI) to discriminate between live and dead cells.
Live cells show a strongly reduced uptake of the charged cationic
dye PI compared to dead cells [38]. The percentage of dead cells was
assessed using the flow cytometer apparatus (FACScan; Beckton-
Dickinson, San Jose, CA) and the WinMDI 2.8 software WinMDI
v. 2.7 (Scripps Research Institute, La Jolla, CA).
Protein Quantification
Immunoblot images were digitized, and the optical densities of
specific antigen-antibody complexes were quantified using the Gene
Gnome Imaging System supported by the Gene Tools software pack-
age (both from Syngene, Frederick, MD).
Statistical Analysis
Results are presented as mean ± SD of n independent experiments.
Statistical significance was assessed using the 2-tailed Student’s t test.
P < .05 was considered statistically significant.
The Bliss additivism model [39] was used to calculate the expected
effect of combining MJ and wortmannin, Akt inhibitor 1, or 2-DG.
Calculations were done using the following formula: Ebliss = EA + EB −
EA × EB, where EA and EB are the fractional inhibitions obtained
by drug A alone and drug B alone at specific concentrations. Here,
Ebliss is the fractional inhibition that would be expected if the combi-
nation of the two drugs was exactly additive. If the experimentally
measured fractional inhibition is greater than Ebliss, the combination
was said to be synergistic.
Results
Cytotoxicity of MJs Toward Sarcoma and
Carcinoma Cell Lines
The cytotoxic activity of MJ was tested in vitro against four sarcoma
(MCA-105, SaOS-2, SK-LMS, and RD) and four carcinoma (A-549,
B-16, CT-26, and HCT-116) cell lines. Each cell line was exposed
to MJ for 16 hours at concentrations ranging from 0.5 to 3 mM,
and cytotoxicity was determined as described in the Materials and
Methods section. Methyl jasmonate is a plant stress hormone, and we
chose its concentration based on the plasma concentrations achieved
upon administration of a well-studied plant stress hormone, salicylic
acid. Salicylic acid is a nonsteroidal anti-inflammatory drug. Whereas
most nonsteroidal anti-inflammatory drugs (such as indomethacin)
act in the micromolar range, salicylates act in the low millimolar range.
The highest nontoxic pharmacological concentration of salicylate used
in humans is approximately 3 mM [40]. As can be seen in Figure 1, all
cell lines responded in a dose-dependent fashion to MJ.
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Basal Akt Expression Is Correlated with Sensitivity to MJ
in Sarcoma But Not Carcinoma Cell Lines
Because Akt is known to be involved in the resistance of cancer
cell lines toward numerous chemotherapies and cytotoxic agents
[41,42], we hypothesized that this kinase could confer resistance to
MJ as well. To evaluate the basal Akt expression in the different cell
lines, we used Western blot analysis using specific antibodies and
characterized the expression levels of pAkt, indicative of Akt acti-
vation, and Akt. As can be seen in Figure 2A, differential basal levels
of pAkt were observed in the different cell lines. In contrast, basal
total Akt levels were similar in all cell lines.
To evaluate the relationship between basal pAkt expression and the
sensitivity to MJ, we quantified the expression of pAkt and Akt and
examined the correlation between the pAkt/Akt ratio and the cyto-
toxic effect of 1 mMMJ in each cell line. As can be seen in Figure 2B,
a strong inverse correlation was observed between pAkt/Akt ratio and
the cytotoxic effect ofMJ in the sarcoma cell lines (R2 = 0.9028). How-
ever, only poor correlation was observed in the carcinoma cell lines
(R2 = 0.3281).
Methyl Jasmonate Modulates the Levels of pAkt in Sarcoma
Cell Lines
Previous studies have shown that exposure of cells to different che-
motherapies and cytotoxic agents leads to changes in the expression
levels of pAkt [43–45]. Thus, we next determined whether exposure
to MJ will affect the activation of Akt in the sarcoma cell lines. As can
be seen in Figure 2C , treatment with MJ led to a differential re-
sponse in pAkt expression. Methyl jasmonate exposure led to an in-
crease in pAkt levels in MCA-105 and SaOS-2 cell lines and a
decrease in the SK-LMS cell line.
Inhibition of the PI3K/Akt Pathway Sensitizes MCA-105 and
SaOS-2 Cell Lines to MJ
The increase seen in pAkt in MCA-105 and SaOS-2 cells after
treatment with MJ led us to hypothesize that this elevation in pAkt
levels might have a cytoprotective role, which confers relative resis-
tance to the cytotoxic effect of MJ. To determine whether the MJ-
induced increase in pAkt has a protective role, we used two different
inhibitors of the PI3K/Akt pathway. Wortmannin is an irreversible
and highly specific PI3K inhibitor [46]. Akt inhibitor 1 binds to the
pleckstrin homology domain of Akt, disrupting the translocation of
Akt to plasma membrane and its ability to be phosphorylated and ac-
tivated by membrane-bound phosphatidylinositol-dependent kinases
[47]. MCA-105 and SaOS-2 cells were treated with 0.5 to 1 mMMJ,
40 μM wortmannin, 25 μM Akt inhibitor 1, or combinations of MJ
with either inhibitor for 16 hours, and cell viability was quantified.
As can be seen in Figure 3A, in both cell lines, treatment with combi-
nations of MJ and wortmannin yielded a cytotoxic effect that was
greater than the predicted combined cytotoxic effect according to
the Bliss additivism model [39]. Activity of wortmannin was verified
by evaluating pAkt levels by Western blot (Figure 3B). In addition,
treatment of MCA-105 and SaOS-2 cells with a combination of MJ
and Akt inhibitor 1 also yielded a synergistic cytotoxic effect according
to the Bliss model (Figure 3C ).
To further investigate the hypothesis that Akt protects the cells
from the cytotoxic effect of MJ, we next examined the changes in pAkt
levels in response to exposure of MCA-105 cells to MJ and the Akt
inhibitor. As can be seen in Figure 3D, treatment with MJ resulted
in an increase in pAkt and its downstream substrates pGSK-3α/β
levels, whereas, as expected, treatment with Akt inhibitor 1 resulted
in a decrease in pAkt and pGSK-3α/β levels. Interestingly, the combi-
nation of MJ and the Akt inhibitor resulted in reduced levels of pAkt
and pGSK-3α/β levels compared with MJ by itself. Thus, it can be
concluded that treatment with the Akt inhibitor prevented the MJ-
induced increase in pAkt in MCA-105 cells.
Overexpression of Constitutively Active Akt in MCA-105 Cells
Confers Protection from the Cytotoxic Effect of MJ
Because inhibition of Akt sensitized MCA-105 cells to the cyto-
toxic effect of MJ, we sought to examine the effects of overexpression
of constitutively active Akt on MJ-induced cytotoxicity. MCA-105
cells were transiently transfected with a GFP-encoding vector (used
as control), myr-Akt (encoding a constitutively active Akt) or myr-
KD-Akt K179A (encoding an inactive Akt), and Akt levels were
Figure 1. The cytotoxic effect of MJ toward sarcoma (left panel) and carcinoma (right panel) cell lines. SaOS-2, SK-LMS, MCA-105, RD,
A-549, B-16, HCT-116, and CT26 cells were seeded into 96-well plates at a concentration of 3 × 103 cells per well and were allowed to
adhere overnight. Cells were incubated for 16 additional hours in the presence of vehicle (ethanol) or different concentrations of MJ. The
cytotoxic effect of MJ was measured using the XTT Cell Proliferation Kit as described in the Materials and Methods section. Values are
means ± SD of at least three similar experiments.
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measured by Western blot analysis (Figure 4A). Next, myr-Akt- and
myr-KD-Akt K179A-transfected cells were treated with 3 mM MJ
for 2.5 hours, and cytotoxicity was evaluated using PI exclusion by
FACS analysis. As can be seen in Figure 4B, the cytotoxic effect of
MJ was significantly greater in myr-KD-Akt K179A-transfected cells
(47.36%) than in myr-Akt–transfected cells (25.2%).
Glucose Metabolism Plays a Significant Role in Resistance of
MCA-105 Cells to MJ-Induced Cytotoxicity
The signaling between Akt and glucose metabolism is bidirectional.
On the one hand, activation of Akt leads to increased glycolysis and
glucose uptake. On the other, the presence of glucose and its metab-
olism through glycolysis is required for the antiapoptotic effects of
Akt. Given the role of Akt in MJ-induced cytotoxicity, we sought to
examine the involvement of glucose metabolism in the cytotoxic ef-
fect of MJ.
We have recently shown that combining MJ with 2-DG, an inhibi-
tor of glycolysis, resulted in a synergistic cytotoxic effect in different
cell lines [48]. We therefore studied the effect of this combination
in MCA-105 cells. As can be seen in Figure 5, in accordance with
our previous results, combination of MJ (0.5, 1 mM) and 2-DG (1,
2 mM) resulted in a synergistic cytotoxic effect. To further investigate
the role of glucose in resistance to MJ, we evaluated the cytotoxic
effect of MJ in cells that were grown in the presence (4.5 gr/L) or ab-
sence of glucose. As expected, cells that were grown in the absence of
glucose exhibited increased sensitivity to the cytotoxic effect of MJ
(Figure 6A).
2-Deoxy-D-Glucose Attenuates MJ-Induced Akt Activation and
Functions in a Similar Manner to That of Akt Inhibitor
The fact that glycolysis is required for the activity of Akt, taken
together with the synergistic cytotoxic effect of combining MJ with
Akt inhibitor, as well as with 2-DG, led us to hypothesize that 2-DG
functions in a similar manner to that of the Akt inhibitor. That is to
say, we predicted that 2-DG would block MJ-induced Akt activation
in the cells. As can be seen in Figure 6B, at its lower concentration
(1 mM), 2-DG by itself led actually to an increase in levels of pAkt.
This increase could represent a defense mechanism of the cell toward
the metabolic stress induced by 2-DG. This defense is apparently in-
sufficient, given that 2-DG at this concentration was shown to be
toxic to the cells (Figure 5). At its higher concentration (5 mM),
2-DG by itself led to a decrease in levels of pAkt. Most importantly,
in a similar fashion to the Akt inhibitor, 2-DG (1, 5 mM) abrogated
the MJ-induced elevation in pAkt levels.
Discussion
In this study, we explored the involvement of the PI3K/Akt path-
way in the cytotoxic effect of MJ. We identified a strong correlation
between the susceptibility of cells to MJ and the basal pAkt levels in
Figure 2. Basal pAkt levels in different cell lines, sensitivity to MJ, and modification of pAkt after treatment with MJ. (A) SaOS-2, SK-LMS,
MCA-105, RD, A-549, B-16, HCT-116, and CT26 cells were seeded into six-well plates at a concentration of 0.7 × 106 cells per well and
were allowed to adhere overnight. Total cell lysates were subjected to SDS-PAGE followed by immunoblot analysis using anti-pAkt, anti-
Akt, and antiactin antibodies. (B) Correlation between basal pAkt levels and sensitivity to MJ in sarcoma (top panel) and carcinoma
(bottom panel) cell lines. (C) MCA-105, SK-LMS, and SaOS-2 cells were seeded into six-well plates at a concentration of 0.7 × 106 cells
per well and were allowed to adhere. After the overnight incubations, cells were incubated for 16 additional hours in the presence of
vehicle (ethanol) or MJ (1 mM). Total cell lysates were subjected to SDS-PAGE followed by immunoblot analysis using anti-pAkt, anti-
Akt, and antiactin antibodies.
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sarcoma cell lines. In contrast, a rather weak correlation was found
among the carcinoma cell lines.
We next evaluated MJ-treated sarcoma cells for phosphorylation of
Akt, indicating activation of the kinase. We found that treatment with
MJ resulted in an increase in levels of pAkt in two sarcoma cell lines:
MCA-105 murine fibrosarcoma and SaOS-2 human OS. Because Akt
functions in various survival pathways, the increase in pAkt levels after
treatment with MJ may represent a cellular adaptive response, which
protects the cell from the stress induced by MJ. Thus, although clearly
inflicting cytotoxic effects and leading to cell death, MJ also seems
to trigger a defense mechanism in the cell, which counteracts its own
action. It is thus clear that the adaptive response to MJ needs to be
overcome to maximize the potential cytotoxic effect of MJ.
By combining inhibitors of the PI3K/Akt pathway with MJ, we
were able to block MJ-induced activation of Akt, thus sensitizing
the cells toward the cytotoxic effect of MJ, resulting in a synergistic
cytotoxic effect. These results are in accordance with previous studies,
which report that inhibition of the PI3K/Akt pathway is an effective
approach to sensitize cells to different chemotherapies and apoptotic
stimuli [49–52].
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In contrast to the activation of Akt in MCA-105 and SaOS-2 cells,
pAkt levels were reduced inMJ-treated SK-LMShuman leiomyosarcoma
cells. This decrease may represent different subpopulations within
sarcoma tumors, in which the MJ-induced stress leads to the in-
hibition of the activity of Akt. The decrease in pAkt levels after treat-
ment with different agents has been demonstrated in several studies
[52–56]. In these cases, the cytotoxic effect was mediated, at least in
part, by inhibition of Akt.
Figure 4. Constitutively active Akt protects MCA-105 cells from the cytotoxic effect of MJ. (A) MCA-105 cells were seeded into 24-well
plates at a concentration of 0.4 × 105 cells per well and were transfected with GFP, myr-Akt, or myr-KD-Akt plasmids. Forty-eight hours
after transfection, total cell lysates were subjected to SDS-PAGE followed by immunoblot analysis using anti-Akt antibodies. (B) MCA-
105 cells were seeded into 24-well plates at a concentration of 0.4 × 105 cells per well and were transfected with either myr-Akt or myr-
KD-Akt plasmids. Forty-eight hours after transfection, vehicle (ethanol) or MJ (3 mM) was added to the wells for 2.5 hours. Cells were
collected for FACS analysis to assess cell death with the PI reagent as described in the Materials and Methods section.
Figure 3. Synergistic cytotoxic effect of MJ and PI3K/Akt pathway inhibitors toward MCA-105 and SaOS-2 cells. (A) MCA-105 (left pa-
nels) and SaOS-2 (right panels) cells were seeded into 96-well plates at a concentration of 3 × 103 cells per well and were allowed to
adhere. After incubation, vehicles (ethanol and DMSO), wortmannin (40 μM), and MJ (0.5, 1 mM, 1 hour later) were added for 16 hours.
The cytotoxic effect was measured using the XTT Cell Proliferation Kit as described in the Materials and Methods section. Values are
means ± SD of at least three experiments. Statistical analysis: * Indicates that the experimentally measured combined cytotoxic effect
is greater than the expected additive effect as calculated using the Bliss additivism model. (B) MCA-105 (left panels) and SaOS-2 (right
panels) cells were seeded into six-well plates at a concentration of 0.7 × 106 cells per well and were allowed to adhere. After the
overnight incubations, cells were incubated for 16 additional hours in the presence of vehicle (DMSO) or wortmannin (40 μM). Total
cell lysates were subjected to SDS-PAGE followed by immunoblot analysis using anti-pAkt and anti-Akt antibodies. (C) MCA-105 (left
panels) and SaOS-2 (right panels) cells were seeded into 96-well plates at a concentration of 3 × 103 cells per well and were allowed to
adhere overnight. After the overnight incubations, cells were incubated for 16 additional hours in the presence of vehicles (ethanol and
DMSO), Akt inhibitor (25 μM), and MJ (0.5 mM, added 1 hour later). The cytotoxic effect was measured using the XTT Cell Proliferation
Kit as described in the Materials and Methods section. * Indicates that the experimentally measured combined cytotoxic effect is greater
than the expected additive effect as calculated using the Bliss additivism model. (D) MCA-105 cells were seeded into six-well plates at a
concentration of 0.7 × 106 cells per well and were serum-starved (0.5% FCS) for the duration of the experiment. After the overnight
incubations, cells were incubated for 16 additional hours in the presence of vehicles (ethanol and DMSO), Akt inhibitor (50 μM), and
MJ (1 mM, added 1 hour later). Total cell lysates were subjected to SDS-PAGE followed by immunoblot analysis using anti-pAkt, anti–
pGSK-3α/β, and anti-Akt antibodies.
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Cancer cells show consistent alterations in metabolic regulation
and, in most cases, have defects in regulation of cell death. Several
studies have recently shown that there is an association between these
two phenotypes. This association is maintained through the activity
of Akt. Akt plays key roles in both maintaining glycolytic activity and
promoting cell survival. These two activities are firmly linked, as the
ability of Akt to promote survival and inhibit cell death is dependent
on glucose availability [57]. Given the role of Akt in MJ-induced
cytotoxicity, we decided to examine the involvement of glucose me-
tabolism in this process. Interestingly, we found that modifying the
glycolytic pathway resulted in similar effects to those induced by
modifying the Akt pathway. First, combining MJ with the glycolysis
inhibitor, 2-DG, yielded a synergistic cytotoxic effect compared to
each agent by itself. In addition, cells grown in the absence of glucose
were more susceptible to the cytotoxic effect of MJ than cells grown
in the presence of glucose. Moreover, when evaluating levels of pAkt,
we saw that 2-DG abrogated the MJ-induced elevation in pAkt lev-
els. These results suggest that glucose metabolism is required for the
antiapoptotic effects of Akt. Therefore, inhibiting this metabolism
can sensitize the cells to the cytotoxic effect of MJ.
In 2001, Gottlob et al. [33] have shown that Akt was able to prevent
apoptosis in the presence of 2-DG but not 5-thio-glucose. 2-Deoxy-D-
glucose is a substrate of the first enzyme in the glycolytic pathway, HK,
and can be phosphorylated but not further metabolized. In contrast,
5-thio-glucose is a competitive inhibitor of HK and cannot be phos-
phorylated by it. Thus, the results of that study suggest that the ability
of Akt to inhibit apoptosis is dependent specifically on the first step
of glycolysis. In our study, 2-DG was sufficient to inhibit the anti-
apoptotic effects of Akt, thus sensitizing the cells to MJ-induced cyto-
toxicity. Interestingly, we found a direct effect of 2-DG on pAkt levels,
suggesting that the inhibition of the antiapoptotic effects of Akt was
mediated, at least in part, by direct inhibition of Akt phosphorylation
and subsequent activation. This inhibitory effect of 2-DG on the ac-
tivation of Akt has been reported in a previous study [58] and adds to
the growing body of evidence that suggests glucose metabolism as a
crucial element in Akt-mediated antiapoptotic effects.
The data obtained in this study raise a number of questions: First,
why was sensitivity to MJ poorly correlated with pAkt levels in car-
cinoma cell lines while strongly correlated in sarcoma cell lines? To
answer this question, broad studies need to be performed, which will
screen a wide variety of cell lines and their sensitivity to cytotoxic
agents such as MJ. The next issue is the differential modification
of pAkt levels after MJ treatment. What is the reason for the fact that
some cells display increased Akt activity in response to cytotoxic
stress, whereas in others, this pathway is attenuated? As mentioned
before, we hypothesize that the elevation in pAkt represents an adap-
tive defense response of the cell toward MJ. The cell is activating
survival pathways to overcome the stress induced by MJ. Conversely,
MJ-induced decrease in pAkt levels may represent cells in which the
cytotoxic effect of MJ is mediated, at least in part, by inhibiting the
Akt pathway. This is not the case, however, in our study, because
the decrease in pAkt levels in SK-LMS cells was not accompanied
by any cytotoxic effect at the tested MJ concentration.
The SK-LMS cell line exhibited extensive Akt phosphorylation in
comparison to other cell lines. This extensive Akt phosphorylation cor-
related well with the ability of this cell line to resist the cytotoxic effect
of MJ. Recent data suggest that the PI3K/Akt pathway constitutes an
important survival pathway in SK-LMS cell line [59]. Treatment of
the cells with the PI3K inhibitor, LY 294002, led to dose- and time-
dependent apoptosis. It is thus possible that the concentration of
Figure 5. Synergistic cytotoxic effect of MJ and 2-DG toward MCA-105 cells. MCA-105 cells were seeded into 96-well plates at a
concentration of 3 × 103 cells per well and were allowed to adhere overnight. After incubation, vehicle (ethanol), 2-DG (1, 2 mM),
and MJ (0.5, 1 mM, added 1 hour later) were added to the wells for 16 hours. The cytotoxic effect was measured using the XTT Cell
Proliferation Kit as described in the Materials and Methods section. Values are means ± SD of at least three experiments. * Indicates
that the experimentally measured combined cytotoxic effect is greater than the expected additive effect as calculated using the Bliss
additivism model.
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MJ, which led to a decrease in pAkt levels, was insufficient to induce
death in the cells, yet it was still capable to partially compromise sur-
vival signaling pathways.
The differential response of the three sarcoma cells lines toward
MJ in the cytotoxic effect and modification of pAkt levels may be
explained by the existence of a threshold of Akt activation that must
be reached in order for the antiapoptotic effects of Akt to come into
effect. The notion of the existence of an activation threshold of the
PI3K/Akt pathway has been proposed by previous studies, which
suggest that a sufficient level of activation of Akt might be necessary
to mediate myocardial protection after ischemic preconditioning in
diabetic rat hearts [60] and to maintain normal cell proliferation,
growth, and differentiation [61]. Although MJ induces a decrease in
pAkt levels in SK-LMS cells, these levels remain higher than the ele-
vated levels of pAkt in MJ-treated MCA-105 and SaOS-2 cells, pro-
viding sufficient antiapoptotic signaling to protect SK cells from the
cytotoxic effect of MJ.
Our observation that combination of MJ and Akt inhibitor
yielded a synergistic cytotoxic effect (in cells in which pAkt increased
after MJ treatment) suggests an important role for Akt in the re-
sponse of cells to MJ. It would be of great interest to extensively in-
vestigate the effect of MJ on the numerous downstream effectors
that constitute the Akt pathway, such as mTOR, BAD, IKK, etc.
In this study, we found that both alpha and beta isoforms of the
downstream kinase GSK-3 are altered in a similar manner to pAkt.
The involvement of GSK-3α has been previously shown in several
types of cancers, including colon cancer [62] and multiple myeloma
[63]. Similarly, the beta isoform has been shown to be involved in
Figure 6. Glucose protects MCA-105 cells from the cytotoxic effect of MJ. (A) MCA-105 cells were seeded into 96-well plates at a
concentration of 3 × 103 cells per well and were allowed to adhere overnight. After incubation, medium was replaced with fresh me-
dium in the presence (4.5 g/L) or absence of glucose, and vehicle (ethanol) or MJ was added for 16 additional hours. The cytotoxic effect
was measured using the XTT Cell Proliferation Kit as described in the Materials and Methods section. Values are means ± SD of at least
three experiments. Statistical analysis: *P < .05. (B) MCA-105 cells were seeded into six-well plates at a concentration of 0.7 × 106 cells
per well and were allowed to adhere. After incubation, vehicle (ethanol), 2-DG (1, 5 mM), and MJ (1 mM, added 1 hour later) were added
to the wells for 16 additional hours. Total cell lysates were subjected to SDS-PAGE followed by immunoblot analysis using anti-pAkt and
anti-Akt antibodies. Lower panel: quantification of protein levels.
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several types of cancers, including hepatoma [64] and colorectal can-
cer [65].
Our findings provide evidence to the involvement of GSK-3α/β in
sarcoma and suggest a possible role for GSK-3α/β in MJ-induced cy-
totoxicity and/or the adaptive response of MCA-105 fibrosarcoma
cells toward it.
In conclusion, our results raise the possibility of using combinations
of MJ and Akt inhibitor/2-DG as a novel multicomponent anticancer
therapeutic modality for sarcomas.
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